Welcome to the UPF Digital Repository

GC-MS quantification method for mephedrone in plasma and urine: application to human pharmacokinetics

Show simple item record

dc.contributor.author Olesti Muñoz, Eulàlia, 1991-
dc.contributor.author Pujadas Bastardes, Mitona
dc.contributor.author Papaseit Fontanet, Esther
dc.contributor.author Pérez Mañá, Clara
dc.contributor.author Pozo Mendoza, Óscar J., 1975-
dc.contributor.author Farré Albaladejo, Magí
dc.contributor.author Torre Fornell, Rafael de la
dc.date.accessioned 2017-11-29T08:55:56Z
dc.date.issued 2017
dc.identifier.citation Olesti E, Pujadas M, Papaseit E, Pérez-Mañá C, Pozo ÓJ, Farré M et al. GC-MS quantification method for mephedrone in plasma and urine: application to human pharmacokinetics. J Anal Toxicol. 2017 Mar 1;41(2):100-6. DOI: 10.1093/jat/bkw12
dc.identifier.issn 0146-4760
dc.identifier.uri http://hdl.handle.net/10230/33402
dc.description.abstract Increasing consumption has been observed among young people of new psychoactive substances, including synthetic cathinone derivatives. The most well known of these is mephedrone whose use has been related to acute intoxication and fatality. Several methods able to detect mephedrone have been reported, although to date, none have been applied to human pharmacokinetic studies in a controlled setting. We developed a gas chromatography-mass spectrometry technique for mephedrone quantification in human plasma and urine. Plasma after deproteinization and urine were submitted to a liquid-liquid extraction and derivatization of the extract with MSTFA prior to analysis. Calibration curves covered concentration ranges in plasma between 5 and 300 ng/mL and in urine between 20 and 1,500 ng/mL. The method has been successfully applied to biological samples obtained from a pilot clinical trial intended to evaluate the human pharmacology of mephedrone and its relative bioavailability and pharmacokinetics. Six healthy males were administered 150 mg of mephedrone by the oral route in a randomized, double-blind, cross-over controlled trial. Peak plasma concentration (Cmax = 122.6 ± 32.9 ng/mL) was reached at 1 hour (0.5-2 h) post-drug administration. Mephedrone showed a rapid elimination half-life (t1/2 = 2.2 h) compared to other psychostimulants. Less than 15% of the dose was excreted in urine as a free-form. Mephedrone concentrations displayed a relevant inter-subject variability.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Oxford University Press
dc.relation.ispartof Journal of Analytical Toxicology. 2017 Mar 1;41(2):100-6
dc.rights © Oxford University Press. This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Journal of analytical toxicology following peer review. The definitive publisher-authenticated version Olesti E, Pujadas M, Papaseit E, Pérez-Mañá C, Pozo ÓJ, Farré M. et al. GC-MS quantification method for mephedrone in plasma and urine: application to human pharmacokinetics. J Anal Toxicol. 2017 Mar 1;41(2):100-106 is available online at: https://academic.oup.com/jat/article/41/2/100/2333832
dc.subject.other Sistema nerviós central -- Efecte dels medicaments
dc.title GC-MS quantification method for mephedrone in plasma and urine: application to human pharmacokinetics
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1093/jat/bkw120
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/acceptedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking